Funder
MOH | National Medical Research Council
Walter and Gertrud Sigenthaler Foundation, Zurich
Department of Health | National Health and Medical Research Council
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quere S, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: The LUMIERE study. Retina. 2013;33:474–81.
2. Gillies MC, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology. 2014;121:676–81.
3. Rakic JM, Leys A, Brie H, Denhaerynck K, Pacheco C, Vancayzeele S, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study. Clin Ophthalmol. 2013;7:1849–58.
4. Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, et al. Real-world vision in age-related macular degeneration patients treated with single Anti-VEGF drug type for 1 year in the IRIS Registry. Ophthalmology. 2018;125:522–8.
5. Ehlken C, Ziemssen F, Eter N, Lanzl I, Kaymak H, Lommatzsch A, et al. Systematic review: Non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020;258:2077–90.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献